SCHEMBL25323401

SCHEMBL25323401

Oc1cc(Cl)c2c(Br)cccc2c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.39
CYP3A4 P08684 2/20 0.39
HPGD P15428 2/20 0.39
CRHBP P24387 1/20 0.39
CRHR2 Q13324 1/20 0.39
MEN1 O00255 2/20 0.38
ALDH1A1 P00352 2/20 0.38
KMT2A Q03164 2/20 0.38
DNMT1 P26358 1/20 0.38
CACNA1B Q00975 1/20 0.38
APBA1 Q02410 1/20 0.38
MCL1 Q07820 1/20 0.38
APOBEC3G Q9HC16 1/20 0.38
NQO2 P16083 1/20 0.36
TSHR P16473 1/20 0.35
CYP1A2 P05177 1/20 0.35
ESR1 P03372 3/20 0.35
ESR2 Q92731 3/20 0.35
KDM4E B2RXH2 1/20 0.35
INPPL1 O15357 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22208228 0.86 MEN1 (0.39) HSD17B10CYP3A4HPGDCRHBPCRHR2
SCHEMBL29418778 0.86 MEN1 (0.39) HSD17B10CYP3A4HPGDCRHBPCRHR2
SCHEMBL29903147 0.83 ALDH1A1 (0.40) HSD17B10CYP3A4HPGDMEN1ALDH1A1
SCHEMBL23409296 0.83 ALDH1A1 (0.40) HSD17B10CYP3A4HPGDMEN1ALDH1A1
SCHEMBL31049123 0.82 NQO2 (0.47) HSD17B10CYP3A4HPGDMEN1ALDH1A1
SCHEMBL25352843 0.78 MEN1 (0.41) HSD17B10CYP3A4HPGDMEN1ALDH1A1
SCHEMBL2696664 0.76 CYP1A2 (0.42) HSD17B10CYP3A4HPGDMEN1ALDH1A1
SCHEMBL29428570 0.76 CYP1A2 (0.42) HSD17B10CYP3A4HPGDMEN1ALDH1A1
SCHEMBL26752351 0.76 ALDH1A1 (0.40) MEN1ALDH1A1KMT2ACYP1A2MAPT
SCHEMBL24652313 0.74 ALDH1A1 (0.40) HSD17B10CYP3A4HPGDMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4216951-B1 KRAS G12D INHIBITORS MIRATI THERAPEUTICS INC (US) 2026-04-01 EP disclosed
US-20230357277-A1 KRAS G12D INHIBITORS ARRAY BIOPHARMA INC. 2023-11-09 US disclosed
US-20230357277-A1 KRAS G12D INHIBITORS ARRAY BIOPHARMA INC. 2023-11-09 US disclosed
US-20230357277-A1 KRAS G12D INHIBITORS ARRAY BIOPHARMA INC. 2023-11-09 US disclosed
EP-4216951-A1 KRAS G12D INHIBITORS Mirati Therapeutics, Inc. (US) 2023-08-02 EP disclosed
WO-2022066646-A1 KRAS G12D INHIBITORS Mirati Therapeutics, Inc. (US) 2022-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357277-A1 KRAS G12D INHIBITORS KRAS, NRAS, HRAS HSD17B10 2806/4885CYP3A4 3974/4885HPGD 749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.